Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
301.14
+0.58 (+0.19%)
Streaming Delayed Price
Updated: 12:22 PM EDT, Jul 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about United Therapeutics Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Strong Candidate for GARP Investors
July 09, 2025
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy.
Via
Chartmill
1 Value Stock with Impressive Fundamentals and 2 to Turn Down
July 09, 2025
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...
Via
StockStory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Potential Undervalued Biotech Stock
July 02, 2025
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a financially healthy biotech stock with strong profitability and an undervalued price. Its low P/E and high margins make it a candidate for value investors.
Via
Chartmill
1 Mid-Cap Stock with Exciting Potential and 2 to Ignore
July 01, 2025
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...
Via
StockStory
Forecasting The Future: 7 Analyst Projections For United Therapeutics
June 02, 2025
Via
Benzinga
Earnings Scheduled For April 30, 2025
April 30, 2025
Via
Benzinga
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (9 Ratings)
June 30, 2025
Via
Benzinga
Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday
June 30, 2025
Via
Benzinga
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors
June 17, 2025
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers growth at a reasonable price, with strong profitability, no debt, and a PEG ratio of 0.68. A solid pick for long-term investors.
Via
Chartmill
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?
June 15, 2025
11 large-cap stocks were worst performers last week: SJM, CHWY, IOT, UTHR, CVNA, APP, UAL, GRAB, EIX, LULU, MBLY. Analysts lower price forecasts.
Via
Benzinga
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 to Keep Off Your Radar
June 13, 2025
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...
Via
StockStory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
June 11, 2025
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong profitability, zero debt, and an undervalued stock price, making it a candidate for value investors in the biotech sector.
Via
Chartmill
Dow Gains 50 Points; US Small Business Optimism Index Rises In May
June 10, 2025
Via
Benzinga
Topics
Stocks
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
June 10, 2025
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 10, 2025
Via
Benzinga
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
May 29, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen...
Via
StockStory
Topics
Artificial Intelligence
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge
May 27, 2025
Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics
Via
Benzinga
Topics
Intellectual Property
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors
May 27, 2025
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and a cheap valuation, making it a standout for GARP investors following Peter Lynch's strategy.
Via
Chartmill
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
May 26, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
1 Safe-and-Steady Stock on Our Buy List and 2 to Ignore
May 19, 2025
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
Via
StockStory
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
May 13, 2025
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers.
Via
StockStory
Topics
Artificial Intelligence
UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central
May 13, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its non-GAAP profit...
Via
StockStory
Examining the Quality Attributes of UNITED THERAPEUTICS CORP (NASDAQ:UTHR).
May 09, 2025
A fundamental analysis of (NASDAQ:UTHR): Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) qualifies as a quality stock.
Via
Chartmill
3 Big Reasons to Love United Therapeutics (UTHR)
May 09, 2025
What a brutal six months it’s been for United Therapeutics. The stock has dropped 23.1% and now trades at $308, rattling many shareholders. This might have investors contemplating their next move.
Via
StockStory
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
May 08, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex...
Via
StockStory
Topics
Artificial Intelligence
Following Peter Lynch’s approach: Does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fit the bill?
May 05, 2025
Let’s dive into UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation.
Via
Chartmill
The Top 3 Stock Picks at the World’s Greatest Hedge Fund
May 02, 2025
See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024.
Via
MarketBeat
Topics
Regulatory Compliance
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity
May 01, 2025
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity
Via
Chartmill
1 Value Stock Worth Investigating and 2 to Brush Off
May 01, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...
Via
StockStory
United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1
April 30, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its GAAP profit of...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.